Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 1002 - Shaanxi Micot Technology

Next Previous
X
Search
Drug Profile

MT 1002 - Shaanxi Micot Technology

Latest Information Update: 08 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shaanxi Micot Technology Co
  • Class Cardiovascular therapies; Peptides; Vascular disorder therapies
  • Mechanism of Action Platelet glycoprotein GPIIb-IIIa complex anatgonists; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute coronary syndromes

Most Recent Events

  • 27 Feb 2024 Phase-II clinical trials in Acute coronary syndromes in China (IV) (NCT06533358)
  • 31 Aug 2023 Shaanxi Micot Technology terminates a phase II trial in Acute coronary syndromes (In adults, In the elderly) in USA (IV, Infusion) due to commercial considerations (NCT04723186)
  • 30 May 2023 Shaanxi Micot Technology suspends a phase II trial in Acute coronary syndromes (In adults, In the elderly) in USA (IV, Infusion) due to strategic reasons (NCT04723186)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top